Quantitation of three-month intraindividual variability and influence of sex and menstrual cycle phase on CYP1A2, N-acetyltransferase-2, and xanthine oxidase activity determined with caffeine phenotyping

被引:66
作者
Kashuba, ADM
Bertino, JS
Kearns, GL
Leeder, JS
James, AW
Gotschall, R
Nafziger, AN
机构
[1] Bassett Healthcare, Clin Pharmacol Res Ctr, Cooperstown, NY 13326 USA
[2] Bassett Healthcare, Dept Med, Cooperstown, NY 13326 USA
[3] Bassett Healthcare, Dept Pharm Serv, Cooperstown, NY 13326 USA
[4] Childrens Mercy Hosp, Div Pediat Clin Pharmacol & Expt Therapeut, Kansas City, MO 64108 USA
[5] Univ Missouri, Dept Pediat, Kansas City, MO 64110 USA
[6] Univ Missouri, Dept Pharmacol, Kansas City, MO 64110 USA
关键词
D O I
10.1016/S0009-9236(98)90105-9
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objective: To evaluate intraindividual variability and the effects of sex and menstrual cycle phase on the activity of cytochrome P450 IA2 (CYPIA2), N-acetyltransferase 2 (NAT2), and xanthine oxidase. Methods: Ten white men were given 2 mg/kg caffeine orally every 14 days for 3 months. The same dosage of caffeine was given to 10 premenopausal white women during the midfollicular and midluteal phases of three complete menstrual cycles. Phenotype was determined with urinary caffeine metabolite ratios. Results: For CYPIA2, mean metabolic ratio (+/-SD) was 5.97 +/- 2.78 during the midfollicular phase and 5.32 +/- 1.99 during the midluteal phase (p = 0.2). For extensive and poor metabolizers of NAT2, mean midfollicular phase metabolite ratios were 0.71 +/- 0.060 and 0.37 +/- 0.030, and mean midluteal phase metabolite ratios were 0.69 +/- 0.076 and 0.39 +/- 0.053 (p = 0.9). For xanthine oxidase, mean midfollicular-phase metabolite ratio was 0.63 +/- 0.06 and mean midluteal phase metabolite ratio was 0.63 +/- 0.05 (p = 0.3). Among the men, mean CYPIA2, NAT2 rapid and slow acetylator, and xanthine oxidase indices were 9.42 +/- 10.18, 0.66 +/- 0.021, 0.31 +/- 0.056, and 0.64 +/- 0.03. There were no differences in metabolite ratios between men and women for CYPIA2, NAT2 extensive metabolizers, or xanthine oxidase. A statistically significant sex difference was found for poor metabolizers of NAT2 (p < 0.05). Median coefficients of variation for CYPIA2, NAT2 extensive and poor metabolizers, and xanthine oxidase ratios were 16.8% (range, 4.5% to 49.3%), 2.9% (range, 2.2% to 4.7%), 13.4% (range, 7.5% to 27.2%), and 4.5% (range, 2.3% to 13.0%). Conclusion: Stratification by menstrual cycle phase or sex need not be performed for pharmacokinetic or clinical investigations of substrates for CYPIA2, NAT2, or xanthine oxidase in which the subjects are adults.
引用
收藏
页码:540 / 551
页数:12
相关论文
共 40 条
  • [1] The influence of ethnic factors and gender on CYP1A2-mediated drug disposition: A comparative study in Caucasian and Chinese subjects using phenacetin as a marker substrate
    Bartoli, A
    Xiaodong, S
    Gatti, G
    Cipolla, G
    Marchiselli, R
    Perucca, E
    [J]. THERAPEUTIC DRUG MONITORING, 1996, 18 (05) : 586 - 591
  • [2] INFLUENCE OF THE MENSTRUAL-CYCLE ON THEOPHYLLINE PHARMACOKINETICS IN ASTHMATICS
    BRUGUEROLLE, B
    TOUMI, M
    FARAJ, F
    VERVLOET, D
    RAZZOUK, H
    [J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1990, 39 (01) : 59 - 61
  • [3] DETERMINATION OF CYP1A2 AND NAT2 PHENOTYPES IN HUMAN-POPULATIONS BY ANALYSIS OF CAFFEINE URINARY METABOLITES
    BUTLER, MA
    LANG, NP
    YOUNG, JF
    CAPORASO, NE
    VINEIS, P
    HAYES, RB
    TEITEL, CH
    MASSENGILL, JP
    LAWSEN, MF
    KADLUBAR, FF
    [J]. PHARMACOGENETICS, 1992, 2 (03): : 116 - 127
  • [4] A URINARY METABOLITE RATIO THAT REFLECTS SYSTEMIC CAFFEINE CLEARANCE
    CAMPBELL, ME
    SPIELBERG, SP
    KALOW, W
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1987, 42 (02) : 157 - 165
  • [5] CARTWRIGHT RA, 1982, LANCET, V2, P842
  • [6] GENETICALLY-DETERMINED VARIABILITY IN ACETYLATION AND OXIDATION - THERAPEUTIC IMPLICATIONS
    CLARK, DWJ
    [J]. DRUGS, 1985, 29 (04) : 342 - 375
  • [7] PREDICTION OF CREATININE CLEARANCE FROM SERUM CREATININE
    COCKCROFT, DW
    GAULT, MH
    [J]. NEPHRON, 1976, 16 (01) : 31 - 41
  • [8] GENTAMICIN THERAPY
    DEVINE, BJ
    [J]. DRUG INTELLIGENCE & CLINICAL PHARMACY, 1974, 8 (11): : 650 - 655
  • [9] DRAYER DE, 1977, CLIN PHARMACOL THER, V22, P251
  • [10] Evans D., 1992, Protein engineering: Proceedings of an AFRC conference on protein engineering in the agricultural and food industry, Selwyn College, Cambridge, 16-17 September 1991., P95